Castle Biosciences vs Starling Oncology
Starling Oncology reported revenue of $503 million in fiscal 2025, 1.5 times Castle Biosciences' $344 million in fiscal 2025. Castle Biosciences' revenue grew 3.7% in its latest year, and Starling Oncology's grew 27.8%. Castle Biosciences had an operating margin of -12.4%, against -7.2% at Starling Oncology. Free cash flow was $28 million at Castle Biosciences and −$28 million at Starling Oncology.
Side by side
| Castle Biosciences | Starling Oncology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $344M | $503M |
| Revenue growth | 3.7% | 27.8% |
| Revenue growth a year, last 5 years | 40.6% | 21.8% |
| Gross margin | 79.4% | — |
| Operating margin | −12.4% | −7.2% |
| Net margin | −7.0% | −12.1% |
| Free cash flow | $28M | −$28M |
| Free cash flow margin | 8.2% | −5.5% |
| Return on capital | −19.1% | −75.7% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.9% | 23.1% |
| Last close | $33.79 | $3.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 4 of 9 | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Castle BiosciencesStarling Oncology
Operating margin
Percent of revenue
Castle BiosciencesStarling Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Castle BiosciencesStarling Oncology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Castle Biosciences and Starling Oncology pages.